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X-linked intellectual disability type Nascimento (MIM #300860), caused by mutations in UBE2A (MIM *312180), is
characterized by craniofacial dysmorphism (synophrys, prominent supraorbital ridges, deep-set, almond-shaped
eyes, depressed nasal bridge, prominent columella, hypoplastic alae nasi, and macrostomia), skin anomalies
(hirsutism, myxedematous appearance, onychodystrophy), micropenis, moderate to severe intellectual disability (ID),
motor delay, impaired/absent speech, and seizures. Hitherto only five familial point mutations and four different
deletions including UBE2A have been reported in the literature.
We present eight additional individuals from five families with UBE2A associated ID - three males from a
consanguineous family, in whom we identified a small deletion of only 7.1 kb encompassing the first three exons
of UBE2A, two related males with a UBE2A missense mutation in exon 4, a patient with a de novo nonsense
mutation in exon 6, and two sporadic males with larger deletions including UBE2A. All affected male individuals
share the typical clinical phenotype, all carrier females are unaffected and presented with a completely skewed
X inactivation in blood. We conclude that 1.) X-linked intellectual disability type Nascimento is a clinically very
distinct entity that might be underdiagnosed to date. 2.) So far, all females carrying a familial UBE2A aberration
have a completely skewed X inactivation and are clinically unaffected. This should be taken in to account when
counselling those families. 3.) The coverage of an array should be checked carefully prior to analysis since not all
arrays have a sufficient resolution at specific loci, or alternative quantitative methods should be applied not to
miss small deletions.
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Global developmental delay and intellectual disability
(ID, IQ < 70) affects up to 3% of the general Western
population. X-linked gene defects account for about 10–
12% in affected males, and more than 90 X-linked genes
causative for ID have been identified [1,2].
X-linked syndromic intellectual disability type Nascimento
(MIM #300860) was first described as a distinct entity in
2006 by Nascimento and colleagues [3], who found a* Correspondence: alma.kuechler@uni-due.de
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reproduction in any medium, provided the ornonsense mutation in UBE2A (MIM *312180, alternative ac-
ronyms RAD6A, HHR6A) in three intellectually disabled
males of a two generation family. Since then, only four fur-
ther mutations [4,5] and four different deletions [6,7] have
been published. The syndrome is characterized clinically by
1.) a pronounced retardation of psychomotor
development, i.e. severe impairment or complete
lack of speech development, walking ages between 1
and 5 years or no walking ability at all, and seizures
in some patients,
2.) a recognisable face (wide face, synophrys, prominent
supraorbital ridges, deep-set, almond-shaped eyes,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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depressed nasal bridge, prominent columella and
hypoplastic alae nasi, macrostomia with downturned
corners of the mouth), and a large head
circumference or macrocephaly,
3.) skin abnormalities (generalized hirsutism, dry skin,
hair whorls, onychodystrophy especially of the feet,
and myxedematous appearance), and
4.) urogenital abnormalities (micropenis,
cryptorchidism, widely spaced nipples, renal
malformations).
Other, less frequently reported associations are malformations
of the fingers or toes, heart defects, congenital cataracts,
and preauricular pits. White matter abnormalities have
been observed in cranial MRI scans [3,6,7].
Here, we describe eight individuals from five families
carrying UBE2A point mutations or deletions and fur-
ther delineate the phenotypic spectrum of this entity.
Materials and methods
Patients
Eight previously not described patients with intellectual
disability type Nascimento were included in this study.
Clinical evaluation was carried out at the Departments
of Medical Genetics in Essen, Murcia, Tübingen, London
and Sheffield. Written informed consent to the study
was obtained from the legal representatives of each par-
ticipant and written consents for publication of the
clinical photographs were given. The investigations
were performed in accordance with the Declaration of
Helsinki protocols.
DNA extraction
Genomic DNA was extracted from peripheral blood
samples using DNA extraction kits and standard proto-
cols (FlexiGene, Qiagen, Hilden, Germany).
Array CGH analysis
Array CGH analysis in the index patients of family A
was performed using a 180 K oligonucleotide array
(Cytochip v1.0, BlueGnome, Cambridge, UK). Patients 7
and 8 were analysed using a NimbleGen 135 k WGT
CGH microarray with a calculated functional resolution
of 0.2 Mb (95% confidence limits). Sample and reference
DNAs (peripheral blood) were fluorescently labelled
(Cy3-dUTP, Cy5-dUTP) and hybridized according to the
manufacturer's protocols (BlueGnome, Cambridge, United
Kingdom; NimbleGen Arrays User’s Guide: CGH and
CGH/LOH Arrays v9.1, Roche NimbleGen, Madison, WI,
USA). Scanning and image acquisition of the Cytochip
was performed on an Agilent microarray scanner, scan-
ning of the NimbleGene microarray on an Axon GenePix
4400A Scanner using GenePix Pro 7 software (MolecularDevices, Sunnyvale, CA, USA). Cytochip data analysis was
carried out using BlueFuse Multi software (BlueGnome).
NimbleGene array raw data was normalized, LOESS cor-
rection applied and the data ratios calculated using DEVA
v1.01 Software (Roche NimbleGen). The normalized data
was processed using Infoquant Fusion v6.0 software
(Infoquant, London, UK) with analysis call settings of 3
consecutive probes +/−0.4 Cy3/Cy5 ratio.
Data interpretation was based on the February 2009
human genome sequence assembly (GRCh37/hg19).
Conspicuous regions were compared with known
CNVs, as provided by the Database of Genomic Variants
(http://dgv.tcag.ca/).
Quantitative real-time PCR (qPCR)
The presence of the UBE2A intragenic deletion in fam-
ily A was investigated by a quantitative real-time PCR
assay using the Roche Universal ProbeLibrary System.
Part of exon 2 was amplified with primers UBE2A_left:
5'-GTCTGTCTTCCCGAAGGTTG-3' and UBE2A_right:
5'-AATGACCGCGTTCCACAC-3', and detected with the
universal probe #19. As an internal control, an assay for
the AS-SRO on chromosome 15 was used. The analysis
was performed on the LightCycler 480 (Roche). Data were
analyzed with the Advanced Relative Quantification
method implemented in the LightCycler 480 Software,
v1.5.
Real Time quantitative PCR in patients 7 and 8 was
carried out using primers (Sigma-Aldrich, St. Louis,
USA) from within the UBE2A gene. Primers were
checked for specificity by melt curve analysis and run on
a StepOne Plus Real Time PCR system (Life Technologies
Applied Biosystems, California, USA) using the SYBR
Green comparative ΔΔCT method. Primers from within
genes ACTBL2 and MANEA were used as endogenous
control sequence targets. Results were processed using
StepOne Plus Software v2.2 with copy number loss or gain
indicated by relative quantitation values (RQ).
Sanger sequencing
For mutation analysis of patient 4,UBE2A (ENSG00000077721)
coding sequence and adjacent intronic sequences of
the longest transcript (ENST00000371558) were taken
from ENSEMBL genome browser (http://www.ensembl.
org/). Intron-based exon specific primer pairs were
designed with Primer3 [8,9]. UBE2A exons were ampli-
fied using the FastStart Taq DNA Polymerase, dNTPack
(Roche) and purified with AmpureXP (Beckman Coulter,
Inc) following standard protocols. BigDye Terminator v3.1
Cycle Sequencing Kit was used for sequencing reactions
prior to sequencing on a 48-capillary 3730 DNA
Analyzer (Applied Biosystems). Sequencing result files
were analysed using Megalign (DNASTAR, Inc) and
Chromas Version 1.45.
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Patient 6 was tested by X-exome analysis, i.e. a next-
generation sequencing approach targeted at the coding
regions of the X chromosome. In short, a fragmented
DNA sample was enriched for the coding and flanking
intronic regions of the X chromosome using the Agilent
SureSelectXT X-Chromosome in-solution target enrich-
ment kit (Agilent, Santa Clara, CA), and sequencing was
performed using the Illumina GAIIx sequencer (2 × 76
paired-end sequencing) (Illumina, San Diego, CA, USA).
Putatively pathogenic variants were validated by conven-
tional Sanger sequencing.
We used PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/), SIFT (http://sift.bii.a-star.edu.sg) and Mutation
Taster (http://www.mutationtaster.org/) to predict the
possible impact of a missense mutation on the structure
and function of the protein.
X chromosome inactivation analysis
To assess the inactivation status of the X chromosome,
DNA methylation of the CAG repeat was studied at the
androgen receptor locus (AR, Xq12, [10]) and the
Fragile-X mental retardation gene locus (FMR1, Xq27.3,
[11]). Undigested DNA samples and DNA samples
digested with the methylation sensitive enzyme HpaII
were amplified with fluorescence-tagged PCR primers.
A male donor was included as a control for complete
HpaII digestion. Fragment length analysis of the PCR
products was performed on an ABI 3130XL genetic
analyser and the GeneMarker software (Softgenetics,
State College, PA, USA). The degree of X inactivation
was calculated as (pd1/pu1)/(pd1/pd1 + pd2/pd2), where
pd1 and pd2 represent the peak integrals of the stronger
and weaker HpaII-digested allele, respectively and pu1
and pu2 are the corresponding peak integrals from the
undigested samples.
Results
Family A (patients 1–3)
This family presented with two developmentally retarded
brothers (patients 1 and 2 in Additional file 1: Figure S1)
born to healthy consanguineous parents, and another re-
tarded second degree maternal cousin (patient 3 in
Additional file 1: Figure S1). Besides the two affected
brothers, there was one more severely developmentally
retarded brother, who suffered from L2-hydroxyglutaric-
aciduria, which had been excluded in patients 1 and 2.
Patient 1 was born after 38 gestational weeks by Cae-
sarean section. Birth measurements are unknown. He re-
quired phototherapy because of hyperbilirubinaemia. He
crawled at the age of 18 months and walked at the age
of 3 years. To this day, he had no expressive language.
He was reported to have suffered from abscesses of the
abdominal skin and perianal region, and from chronicconstipation. He was educated in a school for children
with special needs and has been living in a children’s
home since the age of 12 years because of aggressive be-
haviour towards his siblings at home. Intermittently, he
was reported to exhibit self-mutilating behaviour, which
has improved in the past few years. Since the age of
19 years, he has been suffering from generalized sei-
zures. Sleep is often disturbed by waking periods with
babbling. A cranial MRI has not been performed. Upon
clinical examination at the age of 19 11/12 years, he was
1.59 m tall (−2.75 SD), had a weight of 68 kg (BMI
26.9 kg/m2) and an OFC of 58 cm (+1.22 SD). He
showed a synophrys, tented upper lip, macrostomia,
prominent ears (see Figure 1A), proximally inserted
thumbs (see Figure 1G), overriding second toes on both
feet, and mild onychodystrophy of the feet (see Figure 1L).
There seemed to be a rudimentary speech comprehension
and ability to follow simple instructions, but no ex-
pressive language. Basic communication was facilitated
by gestures.
Patient 2 was born spontaneously after 38 gestational
weeks. Birth measurements are unknown. Like his brother,
he was treated with phototherapy for hyperbilirubinaemia.
He crawled at the age of 18 months and walked at the age
of 3 years. He has no expressive language but communi-
cates with gestures. He is educated in a school for children
with special needs and is said to have a friendly and helpful
temperament. Sleep is light but generally normal. Chronic
constipation has been present since birth. A cranial MRI
has not been performed. Like his affected brother, he had
no formal developmental testing. According to his mother,
his mental development is at the stage of a 5-year-old.
Hearing was normal, ophthalmological evaluation showed
no pathological results except for myopia. A single event
resembling a generalized seizure in childhood has been
reported. Upon his examination at the age of 11 6/12 years,
he was 1.46 m tall (−0.2 SD), had a weight of 34 kg (BMI
15.95 kg/m2) and an OFC of 52.5 cm (−0.72 SD). He
showed a synophrys, tented upper lip, macrostomia (see
Figure 1B), prominent ears with a preauricular pit on the
right hand side and onychodystrophy of the feet (see
Figure 1H and 1M). Two bald spots were present in
the occipital region. Lower legs were slightly oedematous.
Like his brother, he had rudimentary speech comprehen-
sion but no expressive language.
Patient 3, the brothers’ second degree cousin, was
independently presented as well. He was born after
38 weeks of pregnancy with a birth weight of 3210 g
(−0.23 SD) and a length of 50 cm (−0.48 SD). Birth OFC
or OFC in early childhood were not recorded. After birth,
he exhibited hyperbilirubinaemia, a ventricular septum
defect and renal reflux. Developmental delay was evident
from the age of 6 months. Starting at an age of 7 months,
the patient developed seizures. He was examined at the age
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Figure 1 Clinical photographs of our cohort. Upper row (A-F): Facial phenotypes. Facial phenotype is characterized by a broad face, flat
midface, synophrys and/or prominent eyebrows, almond shaped eyes, low nasal bridge, prominent columella of the nose, hypoplastic alae nasi,
and macrostomia. A: Patient 1 (family A) at age 19 years, B: Patient 2 (brother of Patient 1, family A) at age 11 years, C: Patient 4 (family B) at age
15 years, D: Patient 5 (family B) at age 38 years, E: Patient 6 at age 7 years, F: Patient 7 at age 5 years. Depending on the ethnic background,
synophrys can be only very mild or even absent in individuals with light skin and hair pigmentation (e.g. Patients 6 and 8). Middle row (G-K)
Hands of patients in our cohort with proximally inserted thumbs and short distal phalanges. G: Patient 1. H: Patient 2. I: Patient 3. J: Patient 4. K:
Patient 6. Lower row (A-F) Feet. L: Patient 1 with onychodystrophy especially of the first and fifth toe nail (on the right respectively left hand
side). M: Patient 2 with onychodystrophy and sandal gap. N: Patient 3 with sandal gap (status after trauma of the first toe nail). O: Patient 4 with
pes cavus. P: Patient 6 with clubbed toe nail.
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a weight of 18 kg (15.43 kg/m2) and an OFC of 49 cm
(−2.44 SD). He had hypertelorism, a flat nasal bridge,
synophrys, proximally inserted thumbs (see Figure 1I),
mild onychodystrophy of the feet (Figure 1N) and a lumbar
hypertrichosis. He had almost no expressive language (used
the words for mother and father), could crawl and walk
with support. Cranial MRI showed occipital hyperintense
spots that were considered to have been caused by
microembolisms leading to focal hypoxia.
Array CGH analysis in patient 2 revealed a small
deletion with a minimal size of 7.1 kb encompassing
exons 1 to 3 of the UBE2A gene (arr[hg19] Xq24
(118,679,517x1,118,706,962-118,714,074x0,118,714,378x1)
mat, see Figures 2 and 3). The deletion was confirmed
by qPCR. The same deletion was diagnosed in his af-
fected brother (patient 1) and in his cousin (patient 3).
The clinically unaffected mothers were confirmed tobe heterozygous carriers of the deletion. In both fe-
males, X inactivation in blood was completely skewed
(ratio 100:0).
Family B (patients 4 and 5)
Patient 4 (Figure 1C) was the second child of non-
consanguineous, Spanish parents. The father had amaurosis
on the left side attributed to perinatal factors; mother and
sister were healthy. He had a maternal uncle with ID,
epilepsy and similar dysmorphic features (Patient 5).
There was a female first cousin of the maternal grand-
mother with ID of unknown aetiology. Neither clinical in-
formation nor blood was available from her (for pedigree,
see Additional file 2: Figure S2).
Patient 4 was born at 39+4 weeks of gestation, after an
uneventful pregnancy and delivery, with weight 3750 g
(+0.61 SD), length 51 cm (−0.39 SD) and OFC 33 cm
(−1.77 SD). APGAR score was 5/8/10. Dysmorphic features
AFigure 2 Comparison of the three Xq24 deletions encompassing UBE2A detected in this study (black bars) and the four deletions
previously published in the literature (grey bars [6,7]. The smallest deletion (family A) is just 7.1 kb in size and only affects exons 1–3 of
UBE2A.
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pineal gland cyst (with no other brain anomalies in the cra-
nial MRI) was surgically removed. The patient had recurrent
respiratory and ear infections in childhood, his psychomotor
development was delayed (walking at 18 months, marked
speech delay). Because of his ID, he attends a special educa-
tion school. He has no hearing impairment and has not
exhibited seizures, regression or autistic behaviour.
Physical examination (Figure 1C, 1J, 1O) at the age of
15 years showed a height of 161 cm (−1.1 SD), a weight of
51.9 kg (BMI 20.02 kg/m2) and an OFC of 54 cm (−0.84
SD). He had thick eyebrows, synophrys, upslanting palpebralp.P7
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Figure 3 Scheme of the UBE2A gene, showing the position of the new
(in black, above; modified after [4]).fissures, light-green iris, a short nose, prominent chin and
low-set ears, crowded teeth, highly arched feet, and a bilat-
eral single palmar crease. Genitalia were normal male. Joints
were slightly hyperextensible. There was dry skin and
generalized hirsutism. Ophthalmologic evaluation showed
hyperopia (5 dioptres) and astigmatism (1 dioptre); the
skeletal survey showed subluxation of second and third
metatarsophalangeal joints of right foot; the abdominal
ultrasound and cardiac evaluations had normal results.
High resolution karyotype, Fragile-X, subtelomeric MLPA
and MLPA of X-linked ID genes (kit MRX106, including












ly identified (in red, below) and previously published mutations
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SCL6A8; MRC Holland) and array CGH (Ag 400 k,
Qgenomics, Barcelona) had revealed normal results.
Patient 5 (Uncle of patient 4, Figure 1D) was the fifth
child of a healthy and non-consanguineous Spanish
couple. It was a diamniotic, dichorionic twin pregnancy.
The mother suffered from nausea and vomiting during
the whole pregnancy and had a seasonal flu in the sec-
ond trimester. The patient was the second twin and was
born at term by vaginal dystocic delivery. APGAR score
was not recorded, but he needed resuscitation. His birth
weight was 2800 g (−1.87 SD), birth length and OFC are
unknown. Craniofacial dysmorphic features were starkly
apparent at birth. He walked at the age of 4 years and
showed marked expressive language delay. He had his
first seizure when he was 5 years old and was diagnosed
with temporal lobe epilepsy. Brain CT scan showed no
anomalies. Currently, he communicates with gestures
and few words (six to eight) and displays clumsiness and
frequent falls. He suffers from chronic constipation. Ab-
dominal ultrasound, cardiac and ophthalmological evalu-
ations revealed no anomalies. There seems to be a
hearing impairment although this has not been checked.
During the week he lives in a centre for disabled people.
On examination at age 38 years, he was 165 cm tall
(−1.87 SD), had a weight of 72.7 kg (BMI 26.7 kg/m2)
and an OFC of 58 cm (+1.22 SD). He presented with a
broad face, synophrys, long eyelashes, upslanting palpe-
bral fissures, short nose, macrostomia and down-turned
corners of the mouth (see Figure 1D), short and highly
arched feet and myxoedematous appearance of the skin.
After being aware of this characteristic phenotype, the
diagnosis of X-linked ID type Nascimento was established
in these two male patients clinically and Sanger sequen-
cing of UBE2A was performed directly. By this, a missense
mutation c.236C >G (p.Pro79Arg) in Exon 4 of the
UBE2A gene was detected. All prediction programs used
predicted this substitution to be damaging: PolyPhen-2
predicts this mutation to be probably damaging with a
score of 1.000, SIFT as deleterious with a score of 0.00,
Mutation Taster as disease-causing. The mutation was
confirmed in heterozygous state in the clinically healthy
mother, grandmother and one maternal aunt. All inform-
ative female carriers had a complete skewing of X inacti-
vation in blood (see Additional file 2: Figure S2).
Patient 6 (Figures 1E, 1K, 1P) was born at term with
normal APGAR values, a length of 55 cm (+1.09 SD),
a weight of 4240 g (+1.4 SD) and an OFC of 34 cm
(−1.23 SD). Mother and father were aged 38 and
55 years, respectively. For this reason, an amniocentesis
was performed and resulted in a normal male karyotype
(46,XY). Postnatally, the patient suffered from transient
hypoglycaemia, muscular hypotonia and feeding difficulties
that required surgical implantation of a percutaneousendoscopic gastrostomy tube (PEG). During his childhood,
a global severe retardation with autistic features and cen-
tral motor coordination defect, as well as epilepsy (tonic-
clonic seizures, grand mal seizures and absences) became
apparent. In addition, he had a complex cardiac defect:
double-outlet right ventricle, inlet ventricular septum de-
fect, mitral stenosis, persistent superior vena cava and pul-
monary hypertension, and a hip dysplasia (right > left).
Cranial MRI showed a congenital gyration defect in the
fronto-opercular region and a tumour of the pinealis of
stable size. During his development, progressive global
brain atrophy, progressive thickening of the cranial skull
base, progressive spasticity of the legs and loss of motor
skills were observed. Postnatal karyotype was normal in
blood and fibroblasts (46,XY); subtelomere FISH, 6.0 SNP
array, and investigation of ATR-X (HbH cells, mutation
and deletion analysis) were normal as well. At the age of
7 years, he had a length of 122 cm (−0.32 SD), a weight of
26.1 kg (BMI 17.54 kg/m2), and an OFC of 54 cm (+0.98
SD) He was able to vocalize, but had no expressive speech.
Crawling and walking few steps with support was possible.
Seizures had ceased under valproate therapy. It is assumed
that his much more severe clinical course is aggravated by
complications of the cardiac defect. He also developed
cyanotic lips and finger clubbing.
Patient 6 was included in an exome sequencing study
for identification of X-linked genes responsible for devel-
opmental delay and ID. A nonsense mutation (c.387Gdup;
p.Tyr130Valfs*9) in exon 6 of the UBE2A gene was
detected. This mutation occurred de novo.
Patient 7 (Figure 1F) was born by emergency section for
failure to progress at 38 weeks of gestation. Early pregnancy
screening showed raised nuchal thickness. CVS and anom-
aly scan were normal. His birth weight was 4100 g (+1.81
SD). At, or soon after, birth the patient was diagnosed with
talipes and with an inguinal hernia that required surgery;
and with laryngomalacia, gastro-oesophageal reflux, ven-
tricular septal defect, patent foramen ovale and patent
ductus arteriosus all of which resolved by 2 years of age.
He later developed epilepsy, initially presenting with ab-
sence attacks at 1 year of age but these later progressed to
myoclonic seizures. At the age of 5 years he is able to walk
short distances with support. He has about 20 signs for
communication and several monosyllables such as “ma”
and “da”. He has some self-harming behaviour in the form
of head banging and hand biting when frustrated or upset.
He is very sensitive to noise. However, he is usually able to
communicate his needs; he engages well with people and
laughs frequently. He flaps his arms when excited. He also
has periods of wakefulness at night when he laughs and
chatters to himself. He has persistent neutropenia; respira-
tory infections occur about twice a year and can be
prolonged. MRI showed lack of white matter bulk with
delay in maturation of myelination. There was low
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terminale. Examination showed normal growth parame-
ters, central hypotonia, fine hair, a large anterior fonta-
nelle, upslanting palpebral fissures, a large mouth with
macroglossia and tented lips (Figure 1F). He had normal
fingers and toes.
Array CGH analysis detected a minimal deletion of
261 kb comprising 7 genes/loci including the UBE2A
gene. The deletion turned out to be maternally inherited
(arr[hg19] Xq24(118,564,064x1,118,581,896-118,842,750x0,
118,855,888x1)mat; see Figure 2). X inactivation analysis in
the mother showed a complete skewing in blood.
Patient 8 was born at 36 weeks by Caesarean section
after failed induction of labour. Birth weight was 3640 g
(+1.74 SD). He was tube fed from 1 week until
15 months old. He sat at age 14 months, stood at
18 months and walked with support at 2 ½ years. At
this stage he had a few single words. Investigations
showed truncus arteriosus, ventricular septum defect,
atrial septum defect, patent foramen ovale, and branch
pulmonary artery stenosis. Renal scan was normal. He
initially had a problem with frequent infections but
this has resolved. He has not had a brain MRI. On
examination at age 18 months he was 77 cm tall (−2.05 SD)
and his OFC was 46.5 cm (−1.56 SD). He had hypertelorism,
slightly upslanting palpebral fissures, macrostomia, overrid-
ing second toes, lateral deviation of third fingers, small
penis, hypospadias, and cryptorchidism.
Array CGH analysis revealed a minimal deletion of
38 kb that comprises only two genes, UBE2A and
cXorf56 (arr[hg19] Xq24(118,600,360x1,118,679,518-118,
717,453x0,118,717,653x1)mat; see Figure 2). The dele-
tion was inherited from his mother, who showed a com-
pletely skewed X inactivation in blood.
Discussion
In this study, we present eight new patients from five
families with X-linked ID type Nascimento. Three indi-
viduals of our cohort carry a familial intragenic 7.1 kb
deletion of the first three exons of UBE2A, two carry a
larger deletion encompassing UBE2A and additional
genes, one carries a de novo nonsense mutation and two
carry a familial missense mutation.
These five families expand the mutational spectrum
underlying this entity, since only five different mutations
and four deletions had been described so far. In the ori-
ginal family with X-linked ID type Nascimento [3],
Nascimento and co-workers used a candidate gene ap-
proach after linkage analysis and detected a nonsense
mutation (c.382C > T, p.Gln128*) in UBE2A. Although
the three index patients of Nascimento and colleagues
showed a characteristic clinical phenotype, the next two
families were identified only in 2010 by Budny and co-
workers [4], who also performed linkage analysis andsequencing of relevant candidate genes in their first fam-
ily. Their second family was first diagnosed clinically,
and UBE2A sequencing revealed missense mutations
in both families (c.67G > A, p.Gly23Arg; c.32G > A, p.
Arg11Gln, respectively [3]). At the same time, a Japa-
nese family with two affected boys [7] and three unre-
lated affected individuals [6] were published, all detected
by array analyses carrying larger overlapping deletions of
240 kb – 370 kb, encompassing the UBE2A gene (for clin-
ical characterisation see Table 1, for localisation and af-
fected genes, see Figure 2). Two UBE2A mutations were
published most recently, a missense and a truncating mu-
tation, identified by X-exome sequencing in two families
with two and three affected boys, respectively [5].
On the basis of this still very limited number of cases
published in the last seven years, ID type Nascimento
seems to be a quite rare condition, and UBE2A deletions
and mutations seem to occur with an equal frequency.
These proportions might change with the broader use of
next generation sequencing technologies like X-exome
analysis that will lead to the detection of more under-
lying mutations in individuals with ID and also of
smaller, intragenic deletions.
The detection of this small intragenic deletion of only
7.1 kb in our family 1 (see Figure 2) by the Cytochip v1
180 K array was quite fortunate since this size is on the
one hand below the evaluation threshold of most array
protocols. On the other hand, several array types do
not even cover this locus with sufficient markers (see
Additional file 3: Figure S3). The deletion would have
been missed, for instance, by the Affymetrix arrays.
Therefore, if a specific clinical diagnosis is suspected,
the coverage of an array should be checked carefully
prior to a planned analysis, or alternative quantitative
methods should be applied in order not to miss small
deletions.
Although almost all individuals with ID type Nascimento
were identified first by molecular methods, we assume that
this condition is clinically recognisable. The characteristic
UBE2A phenotype, consistently present in all individuals in
the literature [3-7] as well as in our cohort (see Table 1) in-
cludes intellectual disability (mostly moderate to severe)
with no or almost no expressive speech, limited walking
abilities and a recognisable facial gestalt. The facial pheno-
type is characterized by a broad face, flat midface, almond
shaped eyes, ocular hypertelorism, low nasal bridge, prom-
inent columella of the nose, hypoplastic alae nasi, and
macrostomia. Depending on the ethnic background, a
synophrys can be very mild or even absent in individuals
with light hair and skin pigmentation (see Patients 6 and
8), but still, the eyebrows appear straight, the supraorbital
ridges prominent. Therefore even in patients without the
pronounced synophrys the eye region remains characteris-
tic for this entity.
Table 1 Clinical description of our patients with ID type Nascimento (OMIM #300860), table modified after de Leeuw et al. [6]











Gender M M M M M M M M
Positive family
history
+ + + + + - - -
Consanguinity + + - - - - - -
Gestational weeks 38 38 38 39 40 40 38 36
Birth weight [g]/[SD] n.r. n.r. 3210/-0.23 3750/+0.61 2800/-1.87 4240/+1.4 4100/+1.81 3640/+1.74
Birth length [cm]/[SD] n.r. n.r. 50/-0.48 51/-0.39 n.r. 55/+1.09 n.r. n.r.









Height [cm]/[SD] 159/-2.75 146/-0.2 108/-1.92 161/-1.1 165/-1.89 122/-0.32 98/+0.25 77/-2.05
Weight [kg]/BMI [kg/m2] 68/26.9 34/15.95 18/15.43 51.9/20.02 72.7/26.7 26.1/17.54 16.4/17.1 n.r
OFC [cm]/[SD] 58/+1.22 52.5/-0.72 49/-2.44 54/-0.84 58/+1.22 54/+0.98 50.3/-0.37 46.5/-1.56
Development














+ (starting at 18 months;
progressive spasticity of







Expressive speech - - few words + (first words at
2 years; currently
simple sentences)





















Intellectual disability severe severe severe moderate severe severe severe yes
White matter
abnormalities
n.r. n.r. + - - - + n.r




















Table 1 Clinical description of our patients with ID type Nascimento (OMIM #300860), table modified after de Leeuw et al. [6] (Continued)










Synophrys + + + + + + - -
Macrostomia + + + + + + + +
Short, broad neck + + + - + + - -
Low posterior
hairline
+ + + - + n.r. + -




+ + + + + + + +
Ocular hypertelorism + + + - - + - +
Upslanting palpebral
fissures
+ + - + + - + +
Preauricular pits + (unilateral) - - - - - - -
Urogenital abnormalities
Micropenis - + - - - + - +
Cryptorchidism - - - - - - - +
Hypospadias - - - - - - - +
Renal abnormalities n.r. n.r. vesico-ureteral
reflux




+ + - (lumbar
hypertrichosis)





+ + - - + + - -
Widely spaced
nipples
+ + n.r. - n.r. + + -
Dry skin + + + + + -
Hair whorls + + - - - - -
Onychodystrophy + + - - - - - -
Streaky hyperpigmentation - - inguinal to thigh
(unilateral)
























+ + + - - - -





small, pes cavus clubbed nail on first toe bilateral talipes
equinovarus
2nd toe overlaps 3rd
Proximally inserted
thumbs
+ - + - + + - -
Heart defect - - ventricular septum
defect
















(resolved by 2 years)
Hearing loss - - - – + - - -




- - recurrent respiratory
and ear infections
- - prolonged respiratory
infections neutropenia
-
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http://www.ojrd.com/content/8/1/146Features that are variably present are seizures in al-
most 2/3 of the patients (62%), abnormalities in the cra-
nial MRI in about half of the patients (47%, esp. white
matter abnormalities), genital or renal abnormalities
(e.g. micropenis, ureteral reflux) in about 2/3 of the
patients (in 65%,), hirsutism or other abnormalities of
the skin (e.g., myxedematous appearance, widely spaced
nipples, dry skin, hair whorls and onychodystrophy, espe-
cially of the feet in up to 3/4 of the patients), heart defects,
and less frequently various digital anomalies (proximally
inserted thumbs, short thumbs, short fingers, slender fin-
gers) (see Table 2). According to the original publication
[3], the onset of onychodystrophy is in or after puberty,
which is consistent with the findings in our patients. As in
many syndromes, the phenotype changes with age, and es-
pecially hair and skin pattern become more pronounced
in elder UBE2A patients. In one of our patients (pa-
tient 3), streaky hyper-/hypopigmentation was identi-
fied in the inguinal region, leading to the initial clinical
diagnosis of “Ito syndrome”. Hypopigmented spots were
also described in two of Budny’s patients [4]. Postnatal
hyperbilirubinaemia and severe chronic constipation were
present in patients from one family, possibly as a coinci-
dental finding. If both signs are present more frequently
in X-linked ID type Nascimento than in the general popu-
lation can only be determined by evaluation of larger pa-
tient cohorts. Hearing loss and congenital cataract were
previously described in two patients with deletions [6], but
were not present in any other patients. These findings
could also be due to other genes involved in the deletion
or just have occurred coincidentally.
Neutropenia and frequent respiratory infections oc-
curred in our patient 7. Also patient 4 suffered from fre-
quent respiratory and ear infections and had neutrophil
levels in the range of low normal to mild neutropenic.
Neutrophils were normal in patient 2, 3 and 8 (who ini-
tially also had problems with infections), data for patient
1, 5 and 6 were not available. In the literature, patient C
described by de Leeuw [6] was also found to be neutro-
penic, with hypogammaglobulinemia and a low B cell
count. Recurrent infections also occurred in patient A of
this publication but without detectable immunodefi-
ciency [6]. Nothing is reported on frequent infections or
neutropenia in the other publications [3-7]. Therefore,
the number of cases is too small to draw a conclusion as
to whether neutropenia is an associated finding or oc-
curred coincidentally.
A search in the DECIPHER database ([12], status as of
June 18, 2013) revealed two patients with overlapping
deletions including UBE2A, case 274833 with features of
the autistic spectrum and delayed speech carrying a
280 kb deletion including 5 genes, and case 272966
without documented phenotypic features with a 60 kb
deletion including 3 genes and an additional small 1qduplication. To our knowledge there is no description in
the literature of males with larger deletions containing
Xq24 and especially UBE2A, presumably because larger
aberrations would not have been viable in a male karyo-
type constellation.
Previously, a causal role of neighbouring genes of
UBE2A, such as SLC25A5, in the genesis of heart defects
in patients with UBE2A-encompassing large deletions
has been hypothesized [6,7]. However, in our cohort,
heart defects were not only present in the deletion pa-
tients 7 and 8, but also in two patients with intragenic
aberrations (patient 3 with an intragenic deletion, and
patient 6 with a nonsense mutation). This suggests that
heart defects might be a variable feature of X-linked ID
type Nascimento, and that a UBE2A defect is sufficient
for the development of this sign or is a coincidental
finding.
In our cohort, X inactivation was completely skewed
(about 100:0) in blood of all female carriers of UBE2A
aberrations. All female carriers were clinically unaffected.
This is in accordance with the published results, where all
proven [3-6] or presumptive obligatory female carriers [7]
in whom this analysis was performed had a skewed X
inactivation (see also Table 2). No affected female in-
dividuals are known so far. One can speculate that a
clinical phenotype could occur in female carriers with
random X inactivation.
A similar effect of the X inactivation pattern on pheno-
typic expression is known in female carriers of a MECP2
duplication. The majority of female MECP2 duplication
carriers are unaffected due to a preferred inactivation of
the aberrant X-chromosome. Random X inactivation was
found to cause an associated phenotype in females that is
distinct from those in males but can be as severe [13,14].
Therefore, also in genetic counseling of females with
UBE2A deletions or mutations (especially in prenatal
diagnosis), the X inactivation status should be investi-
gated and in case it is random, possible associated
phenotypic features have to be discussed.
UBE2A (also known as HHR6A or RAD6A, OMIM
*312180) encodes for an ubiquitin conjugating enzyme
(E2). E2 enzymes are together with ubiquitin-activating
enzymes (E1) and ubiquitin ligases (E3) involved in the
ubiquitination process [15].
Until recently, it was not known, how UBE2A or mu-
tations in it exactly affect neuronal function. Very re-
cently, Haddad and co-workers identified RAD6A as a
regulator of Parkin-dependent mitophagy and established
a critical role for RAD6A in maintaining neuronal func-
tion [5]. They could show that drosophila deficient for
dRad6 display defective synaptic function as a conse-
quence of mitochondrial failure. They also investigated
mouse mRad6a (Ube2a) knockout and patient derived
hRad6a (Ube2a) mutant cells and could show that RAD6A






























Pat 6 Pat 7 Pat 8 in total
Mutation Truncating Missense Missense Deletion Deletion Deletion Deletion Truncating Missense Deletion Missense Truncating Deletion Deletion 7 Deletions
p.Q128X p.G23R p.R11Q (370 kb) (350 kb) (240 kb) (360 kb) p.I87Mfs*14 p.R7W (7.1 kb) p.P79R p.Y130Vfs*9 (261 kb) (38 kb) 7 Mutations




yes yes n.r. yes yes yes yes n.r. yes yes yes de novo
mutation





3/3 4/4 1/1 2/2 1/1e 1/1 1/1 2/2 3/3 3/3 2/2 1/1 1/1 1/1 26/26 (100%)
Motor delay 3/3 4/4 1/1 2/2 1/1 1/1 1/1 2/2 3/3 3/3 2/2 1/1 1/1 1/1 26/26 (100%)
Speech impairment 3/3 4/4 1/1 2/2 1/1 1/1 1/1 2/2 3/3 3/3 2/2 1/1 1/1 (1/1) 26/26 (100%)
Facial dysmorphism 3/3 4/4 1/1 2/2 1/1 1/1 1/1 2/2 (3/3) 3/3 2/2 1/1 1/1 1/1 26/26 (100%)
Skin changes 3/3 3/4 1/1 2/2 1/1 0/1 1/1 1/2 2/3 3/3 2/2 1/1 0/1 0/1 20/26 (77%)
Hirsutism 3/3 3/4 1/1 2/2 0/1 0/1 1/1 2/2 0/3 2/3 2/2 0/1 (1/1) 0/1 17/26 (65%)
Urogenital
anomalies
3/3 3/4 1/1 2/2 1/1 1/1 1/1 0/2 2/3 1/3 0/2. 1/1 0/1 1/1 17/26 (65%)
Seizures 3/3 3/4 0/1 2/2 1/1 1/1 1/1 0/2 0/3 2/3 1/2 1/1 1/1 0/1 16/26 (62%)
Behavioural
abnormalities
n.r. 2/2 n.r. n.r. n.r. n.r. n.r. 1/2 2/3 1/3 0/2 1/1 1/1 n.r. 8/14 (57%)
White matter
abnormalities
2/2 0/2 n.r. 2/2 1/1 1/1 0/1 0/1 1/2 0/1* 0/2 0/1* 1/1 n.e. 8/17 (47%)
Heart defect 0/3 0/4 0/1 2/2 1/1 1/1 1/1 1/2 0/3 1/3 0/2 1/1 1/1 1/1 10/26 (38%)
[a] number of affected individuals with available clinical data.
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http://www.ojrd.com/content/8/1/146as an E2 ubiquitin conjugating enzyme interacts with
an E3 ubiquitin ligase such as Parkin resulting in
ubiquitination of mitochondrial proteins to facilitate
the clearance of dysfunctional mitochondria in cells.
The authors postulate that maintaining a healthy mito-
chondrial pool in vivo is critical to maintain normal
synaptic transmission, which is potentially an import-
ant element involved in the aetiology of ID.
Since ID type Nascimento is a clinically recognizable
entity, some differential diagnoses with overlapping phe-
notypes have to be considered. There are mainly two
also X-linked conditions that have to be discussed: in
Cabezas syndrome (MIM #300354), intellectual disability,
severe speech impairment, gait abnormalities, abnormal
hair whorls, small feet, small male genitalia, hypospadias
and cryptorchidism are characteristic features [16].
Mutations in CUL4B have been identified as under-
lying cause [17]. Börjeson-Forssman-Lehmann syn-
drome (BFLS, MIM #301900), caused by mutations or
deletions in PHF6 [18] shares facial characteristics with
X-linked ID type Nascimento (especially prominent
supraorbital ridges, prominent columella and hypo-
plastic alae nasi and coarsening of facial features dur-
ing adolescence) as well as intellectual disability and
small external genitalia in boys. However, intellectual
disability is usually described as mild to moderate in
BFLS patients, in contrast to a moderate to severe de-
gree of intellectual disability in X-linked ID type
Nascimento. Other features of BFLS not usually
present in patients with X-linked ID type Nascimento
are truncal obesity, gynecomastia, tapering fingers and
fleshy ear lobes.
Conclusion
The distinct pattern of facial dysmorphism and other
physical and developmental characteristics of patients with
X-linked ID type Nascimento suggests that this is a
clinically recognizable entity that might be underdiagnosed
to date. So far, all females carrying a familial UBE2A aber-
ration have a completely skewed X inactivation and are
clinically unaffected. This should be taken in to account
when counselling those families. If this condition is clinic-
ally suspected, sequence analysis plus dosage analysis
should be undertaken. The coverage of an array should be
checked carefully prior to an analysis since not all arrays
have a sufficient resolution at this locus, or alternative
quantitative methods like qPCR or MLPA should be ap-
plied not to miss small deletions.
Additional files
Additional file 1: Figure S1. Pedigree of Family A with three affected
individuals (patients 1, 2, 3) with molecularly proven UBE2A deletion and
several individuals showing clinical signs suggestive of X-linked ID typeNascimento based on photos/history (molecular proof was not possible
so far).
Additional file 2: Figure S2. Pedigree and results of X inactivation
study and mutation analysis (electropherograms) in Family B with two
affected male individuals (patients 4 and 5). All three female carriers are
healthy.
Additional file 3: Figure S3. Coverage of the UBE2A region with array
markers – comparison of different commercially available array types
(according to the UCSC browser, hg19, as of June 2013). Not all array
types sufficiently cover the UBE2A region. Two arrays depicted here
(Affymetrix SNP 6.0 and Affymetrix Cytoscan HD array) contain no
markers at all or only markers in the last exon so that intragenic deletions
as in family 1 would have been missed.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
JCC, AK, and DW were involved in design, acquisition and analysis of data,
and drafting of the manuscript. VLG, EGN, DSJ, AM, and AR were involved in
acquisition and analysis of clinical data and made contributions to the draft
of the manuscript. PB, KB, CD, UK, H-JL, DM, and AT were involved in
acquisition and analysis of molecular data and made contributions to the
draft of the manuscript. All authors read and approved the final manuscript.
Acknowledgments
We are grateful to the patients and their families for participating in this
study. We thank Elke Jürgens, Regina Kubica and Christina Lich for excellent
technical assistance. This work was part of the CRANIRARE Network funded
through a grant from the German Ministry of Research and Education to
DW. (BMBF 01GM1211B).
Author details
1Institut für Humangenetik, Universitätsklinikum Essen, Universität Duisburg-
Essen, Hufelandstr. 55, 45122, Essen, Germany. 2Institut für Medizinische
Genetik und Angewandte Genomik, Universitätsklinikum Tübingen,
Tübingen, Germany. 3Unidad de Genética Médica, Servicio de Pediatría,
Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain.
4Sheffield Children’s Hospital, Sheffield, UK. 5MGZ - Medizinisch Genetisches
Zentrum, München, Germany. 6Great Ormond Street Hospital for Children,
London, UK.
Received: 9 July 2013 Accepted: 15 September 2013
Published: 21 September 2013
References
1. Ropers HH: Genetics of early onset cognitive impairment. Annu Rev
Genomics Hum Genet 2010, 11:161–187.
2. Flore LA, Milunsky JM: Updates in the genetic evaluation of the child with
global developmental delay or intellectual disability. Semin Pediatr Neurol
2012, 19:173–180.
3. Nascimento RMP, Otto PA, de Brouwer APM, Vianna-Morgante AM: UBE2A,
which encodes a ubiquitin-conjugating enzyme, is mutated in a novel X-
linked mental retardation syndrome. Am J Hum Genet 2006, 79:549.
4. Budny B, Badura-Stronka M, Materna-Kiryluk A, Tzschach A, Raynaud M,
Latos-Bielenska A, Ropers HH: Novel missense mutations in the
ubiquitination-related gene UBE2A cause a recognizable X-linked mental
retardation syndrome. Clin Genet 2010, 77:541.
5. Haddad DM, Vilain S, Vos M, Esposito G, Matta S, Kalscheuer VM, Craessaerts
K, Leyssen M, Nascimento RM, Vianna-Morgante AM, et al: Mutations in the
intellectual disability gene ube2a cause neuronal dysfunction and impair
parkin-dependent mitophagy. Mol Cell 2013, 50:831–843.
6. de Leeuw N, Bulk S, Green A, Jaeckle-Santos L, Baker LA, Zinn AR, Kleefstra
T, van der Smagt JJ, Vianne Morgante AM, de Vries BBA, et al: UBE2A
deficiency syndrome: Mild to severe intellectual disability accompanied
by seizures, absent speech, urogenital, and skin anomalies in male
patients. Am J Med Genet A 2010, 152A:3084.
7. Honda S, Orii KO, Kobayashi J, Hayashi S, Imamura A, Imoto I, Nakagawa E,
Goto Y-i, Inazawa J: Novel deletion at Xq24 including the UBE2A gene in
a patient with X-linked mental retardation. J Hum Genet 2010, 55:244.
Czeschik et al. Orphanet Journal of Rare Diseases 2013, 8:146 Page 14 of 14
http://www.ojrd.com/content/8/1/1468. Koressaar T, Remm M: Enhancements and modifications of primer design
program Primer3. Bioinformatics 2007, 23:1289–1291.
9. Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, Rozen
SG: Primer3–new capabilities and interfaces. Nucleic Acids Res 2012, 40:e115.
10. Sharp A, Robinson D, Jacobs P: Age- and tissue-specific variation of X
chromosome inactivation ratios in normal women. Hum Genet 2000,
107:343–349.
11. Carrel L, Willard HF: An assay for X inactivation based on differential
methylation at the fragile X locus, FMR1. Am J Med Genet 1996, 64:27–30.
12. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, Van Vooren
S, Moreau Y, Pettett RM, Carter NP: DECIPHER: Database of Chromosomal
Imbalance and Phenotype in Humans Using Ensembl Resources. Am J
Hum Genet 2009, 84:524–533.
13. Grasshoff U, Bonin M, Goehring I, Ekici A, Dufke A, Cremer K, Wagner N,
Rossier E, Jauch A, Walter M, et al: De novo MECP2 duplication in two
females with random X-inactivation and moderate mental retardation.
Eur J Hum Genet 2011, 19:507–512.
14. Bijlsma EK, Collins A, Papa FT, Tejada MI, Wheeler P, Peeters EA, Gijsbers AC,
van de Kamp JM, Kriek M, Losekoot M, et al: Xq28 duplications including
MECP2 in five females: Expanding the phenotype to severe mental
retardation. Eur J Med Genet 2012, 55:404–413.
15. Bhat KP, Greer SF: Proteolytic and non-proteolytic roles of ubiquitin and
the ubiquitin proteasome system in transcriptional regulation. Biochim
Biophys Acta 2011, 1809:150.
16. Cabezas DA, Slaugh R, Abidi F, Arena JF, Stevenson RE, Schwartz CE, Lubs
HA: A new X linked mental retardation (XLMR) syndrome with short
stature, small testes, muscle wasting, and tremor localises to Xq24-q25.
J Med Genet 2000, 37:663–668.
17. Tarpey PS, Raymond FL, O'Meara S, Edkins S, Teague J, Butler A, Dicks E,
Stevens C, Tofts C, Avis T, Barthorpe S, Buck G, Cole J, Gray K, Halliday K,
Harrison R, Hills K, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J,
Raine K, Richardson D, Shepherd R, Small A, Varian J, West S, Widaa S,
Mallya U, et al: Mutations in CUL4B, which encodes a ubiquitin E3 ligase
subunit, cause an X-linked mental retardation syndrome associated with
aggressive outbursts, seizures, relative macrocephaly, central obesity,
hypogonadism, pes cavus, and tremor. Am J Hum Genet 2007, 80:345.
18. Gécz J, Turner G, Nelson J, Partington M: The Börjeson-Forssman-Lehman
syndrome (BFLS, MIM #301900). Eur J Hum Genet 2006, 14:1233–1237.
doi:10.1186/1750-1172-8-146
Cite this article as: Czeschik et al.: X-linked intellectual disability type
Nascimento is a clinically distinct, probably underdiagnosed entity.
Orphanet Journal of Rare Diseases 2013 8:146.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
